BioMark Diagnostics Inc
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer. The company invests in and develops liquid biopsy metabolic panel assay for early stage diagnosis of lung cancer. It has a strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for wo… Read more
BioMark Diagnostics Inc (BMKDF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 0.173x
Based on the latest financial reports, BioMark Diagnostics Inc (BMKDF) has a cash flow conversion efficiency ratio of 0.173x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-189.85K) by net assets ($-1.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioMark Diagnostics Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how BioMark Diagnostics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BioMark Diagnostics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioMark Diagnostics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
20/20 Biolabs, Inc. Common Stock
NASDAQ:AIDX
|
-4.946x |
|
BYON Co. Ltd
KQ:032980
|
0.005x |
|
Rama Phosphates Limited
NSE:RAMAPHO
|
0.011x |
|
PSS EXOL SA D ZY 1
F:9B2
|
N/A |
|
Borealis Foods Inc.
NASDAQ:BRLS
|
0.015x |
|
BPL Limited
NSE:BPL
|
0.003x |
|
Lippo General Insurance Tbk
JK:LPGI
|
0.084x |
|
Ebusco Holding N.V.
F:8J30
|
N/A |
Annual Cash Flow Conversion Efficiency for BioMark Diagnostics Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of BioMark Diagnostics Inc from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-03-31 | $-609.61K | $-982.52K | 1.612x | +102.62% |
| 2023-03-31 | $-1.15 Million | $-914.42K | 0.795x | -58.00% |
| 2022-03-31 | $-635.69K | $-1.20 Million | 1.894x | -81.44% |
| 2021-03-31 | $-79.09K | $-807.30K | 10.207x | +887.71% |
| 2020-03-31 | $-439.13K | $-453.79K | 1.033x | +353.51% |
| 2019-03-31 | $-1.22 Million | $-277.84K | 0.228x | -73.37% |
| 2018-03-31 | $-900.43K | $-770.42K | 0.856x | +731.82% |
| 2017-03-31 | $-1.07 Million | $-109.55K | 0.103x | -94.06% |
| 2016-03-31 | $-554.28K | $-960.01K | 1.732x | +123.15% |
| 2015-03-31 | $147.96K | $-1.11 Million | -7.481x | -441.87% |
| 2014-03-31 | $86.92K | $-120.00K | -1.381x | -- |